NASDAQ:TSHA - Taysha Gene Therapies Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $45.18
  • Forecasted Upside: 374.10 %
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
$9.53
▲ +0.02 (0.21%)

This chart shows the closing price for TSHA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Taysha Gene Therapies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TSHA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TSHA

Analyst Price Target is $45.18
▲ +374.10% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Taysha Gene Therapies in the last 3 months. The average price target is $45.18, with a high forecast of $60.00 and a low forecast of $28.00. The average price target represents a 374.10% upside from the last price of $9.53.

This chart shows the closing price for TSHA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 11 investment analysts is to buy stock in Taysha Gene Therapies.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2021
  • 0 strong buy ratings
  • 13 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/21/2021
  • 0 strong buy ratings
  • 13 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/19/2021
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/18/2021
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/17/2022

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/14/2022JMP SecuritiesReiterated RatingBuy$38.00High
12/16/2021GuggenheimInitiated CoverageBuy$28.00High
12/2/2021Needham & Company LLCReiterated RatingBuy$47.00High
11/11/2021JMP SecuritiesLower Price TargetMarket Outperform$40.00 ➝ $38.00Medium
10/28/2021JMP SecuritiesReiterated RatingBuy$40.00Low
10/6/2021Needham & Company LLCBoost Price Target$45.00 ➝ $47.00Low
9/24/2021JMP SecuritiesReiterated RatingBuy$40.00Low
9/23/2021William BlairReiterated RatingBuyHigh
8/31/2021BTIG ResearchReiterated RatingBuy$44.00Medium
8/31/2021JMP SecuritiesReiterated RatingBuy$40.00Medium
8/18/2021Morgan StanleyLower Price TargetOverweight$43.00 ➝ $39.00Medium
8/17/2021Chardan CapitalLower Price TargetBuy$67.50 ➝ $60.00High
7/15/2021Needham & Company LLCInitiated CoverageBuy$45.00High
7/1/2021Chardan CapitalReiterated RatingBuyHigh
6/24/2021Truist SecuritiesInitiated CoverageBuy$60.00Medium
6/24/2021TruistInitiated CoverageBuy$60.00Medium
6/14/2021BTIG ResearchInitiated CoverageBuy$44.00Low
6/9/2021WedbushInitiated CoverageOutperform$31.00Low
6/8/2021JMP SecuritiesInitiated CoverageOutperform$40.00Medium
5/19/2021Cantor FitzgeraldInitiated CoverageOverweight$44.00Low
4/26/2021Chardan CapitalReiterated RatingBuyMedium
4/13/2021Morgan StanleyBoost Price TargetOverweight$30.00 ➝ $43.00High
4/12/2021Chardan CapitalBoost Price TargetBuy$60.00 ➝ $67.50High
3/8/2021Morgan StanleyBoost Price TargetOverweight$29.00 ➝ $30.00High
3/4/2021Chardan CapitalBoost Price TargetBuy$45.00 ➝ $60.00Low
2/23/2021William BlairInitiated CoverageOutperform$46.00High
1/4/2021OppenheimerInitiated CoverageOutperform$42.00N/A
10/19/2020Chardan CapitalInitiated CoverageBuy$45.00High
10/19/2020Jefferies Financial GroupInitiated CoverageBuy$34.00High
10/19/2020Morgan StanleyInitiated CoverageOverweight$29.00High
10/19/2020The Goldman Sachs GroupInitiated CoverageBuy$31.00Medium
(Data available from 1/17/2017 forward)

News Sentiment Rating

0.55 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/21/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/21/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/20/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/19/2021
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/19/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/18/2021
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/18/2021
  • 3 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/17/2022

Current Sentiment

  • 3 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Taysha Gene Therapies logo
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; and TSHA-102 for the treatment of Rett syndrome. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments; and collaboration with Yale University to advance mini-gene payloads for an AAV gene therapy for the treatment of neurodevelopmental disorders. The company was incorporated in 2019 and is based in Dallas, Texas.
Read More

Today's Range

Now: $9.53
Low: $9.00
High: $9.55

50 Day Range

MA: $12.83
Low: $9.51
High: $15.74

52 Week Range

Now: $9.53
Low: $9.00
High: $33.35

Volume

124,693 shs

Average Volume

110,850 shs

Market Capitalization

$366.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05

Frequently Asked Questions

What sell-side analysts currently cover shares of Taysha Gene Therapies?

The following Wall Street analysts have issued stock ratings on Taysha Gene Therapies in the last year: BTIG Research, Cantor Fitzgerald, Chardan Capital, Guggenheim, JMP Securities, Morgan Stanley, Needham & Company LLC, Truist, Truist Securities, Wedbush, William Blair, and Zacks Investment Research.
View the latest analyst ratings for TSHA.

What is the current price target for Taysha Gene Therapies?

11 Wall Street analysts have set twelve-month price targets for Taysha Gene Therapies in the last year. Their average twelve-month price target is $45.18, suggesting a possible upside of 374.1%. Chardan Capital has the highest price target set, predicting TSHA will reach $60.00 in the next twelve months. Guggenheim has the lowest price target set, forecasting a price of $28.00 for Taysha Gene Therapies in the next year.
View the latest price targets for TSHA.

What is the current consensus analyst rating for Taysha Gene Therapies?

Taysha Gene Therapies currently has 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TSHA will outperform the market and that investors should add to their positions of Taysha Gene Therapies.
View the latest ratings for TSHA.

What other companies compete with Taysha Gene Therapies?

How do I contact Taysha Gene Therapies' investor relations team?

Taysha Gene Therapies' physical mailing address is 2280 Inwood Road, DALLAS TX, 75235. The company's listed phone number is 214-612-0000 and its investor relations email address is [email protected] The official website for Taysha Gene Therapies is www.tayshagtx.com.